With $35M D round, EpicentRx aims to complete clinical testing of cancer immunotherapy

With a $35 million series D, EpicentRx hopes to take its immunotherapy through to an NDA and bring its oncolytic virus program to the clinic.

An undisclosed European investor was the sole investor in the round, which will be split into three tranches and give EpicentRx Inc. about two years of runway, President and CEO Corey Carter told BioCentury. ...